What is Pemvidutide?
Pemvidutide is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune, designed as a once-weekly injectable for obesity and metabolic dysfunction-associated steatohepatitis (MASH). What distinguishes pemvidutide from GLP-1-only agonists like semaglutide is its balanced 1:1 activity at both the GLP-1 and glucagon receptors — the glucagon component adds a mechanism that drives hepatic fat oxidation and energy expenditure, on top of the appetite suppression and gastric emptying delay that GLP-1 agonism provides.
The headline finding from the Phase II MOMENTUM trial was not just the magnitude of weight loss, but the composition of weight lost. Body composition sub-studies (DEXA scans) showed pemvidutide produced weight loss with a notably favorable fat-to-lean mass ratio — a substantial majority of weight lost was fat mass, with relatively less lean mass loss compared to historical GLP-1 monotherapy data. This has made pemvidutide one of the most closely watched compounds among the next generation of GLP-1-class therapeutics, particularly for users concerned about muscle loss during rapid weight loss.
The MASH application is the other major thread — the glucagon receptor component directly addresses hepatic fat accumulation, and pemvidutide showed significant reductions in liver fat content in MASH-focused sub-studies, positioning it as a potential treatment for fatty liver disease independent of its weight loss effects.
For context within the broader GLP-1/glucagon dual-agonist class — Survodutide (Boehringer Ingelheim/Zealand) is a similar dual GLP-1/glucagon agonist further along in trials, and Retatrutide adds a third receptor (GIP) on top of GLP-1/glucagon. Pemvidutide remains earlier-stage than both and is not FDA-approved — it is accessible only through clinical trials or research-chemical sources, the latter carrying significant purity and dosing-accuracy risk for an investigational peptide.
How it works
GLP-1 Receptor Agonism — Appetite and Gastric Emptying
Like semaglutide and other GLP-1 agonists, pemvidutide activates GLP-1 receptors in the hypothalamus to suppress appetite, slows gastric emptying to extend satiety, and improves glucose-dependent insulin secretion. This is the well-established mechanism shared across the entire GLP-1 drug class.
Glucagon Receptor Agonism — Fat-Preferential Energy Expenditure
The differentiating mechanism: glucagon receptor activation in the liver increases fatty acid oxidation (burning stored fat for energy) and raises resting energy expenditure. Glucagon signaling specifically targets hepatic lipid metabolism — reducing liver fat content directly, which is the basis for the MASH application. The combination of reduced caloric intake (via GLP-1) and increased fat oxidation (via glucagon) is thought to underlie the favorable fat-vs-lean body composition outcomes observed in trials, as the energy deficit is met more by mobilizing fat stores than by catabolizing muscle tissue.
The Balanced 1:1 Ratio — A Deliberate Design Choice
Pemvidutide was specifically engineered with equal potency at both receptors (1:1 ratio), distinguishing it from dual agonists with skewed ratios. Altimmune's rationale is that a balanced ratio maximizes the body-composition benefit of the glucagon component while maintaining the appetite-suppression strength of GLP-1 — though head-to-head comparisons against other ratios in humans are not yet available.
What the research shows
What the community reports
Because pemvidutide remains investigational and is not FDA-approved, community experience is limited compared to semaglutide or tirzepatide — most discussion centers on trial results and anticipation rather than widespread self-administration reports. The community that does discuss it tends to be sourcing from research-chemical vendors, which carries meaningfully more risk than other compounds in this library.
Common misconceptions
"Pemvidutide eliminates muscle loss during weight loss."
The body composition data is favorable — a higher proportion of weight lost is fat compared to GLP-1 monotherapy benchmarks — but it doesn't eliminate lean mass loss entirely. Resistance training and adequate protein intake remain necessary to maximize muscle preservation regardless of which GLP-1/glucagon-class compound is used.
"Pemvidutide is basically the same as Survodutide."
Both are dual GLP-1/glucagon agonists, but they are distinct molecules from different companies (Altimmune vs. Boehringer Ingelheim/Zealand) with different receptor binding ratios, half-lives, and trial data. Survodutide is further along in the approval pipeline. They shouldn't be treated as interchangeable, and dosing data for one doesn't directly translate to the other.
"Pemvidutide is available and ready to use like semaglutide."
Pemvidutide is investigational — it has not received FDA approval and is not available through any pharmacy or telehealth channel that semaglutide and tirzepatide use. Any source claiming to sell 'pemvidutide' outside of clinical trials is a research-chemical vendor, with all the purity, dosing-accuracy, and legal risk that implies.
Open PepperLedger to track your protocol →
Free to join. No credit card. Ask the Coach about GLP-1/glucagon dual agonists and body composition strategy.
Free to join · No credit card · 23-day Pro trial included